

MINUTES
INSTITUTIONAL BIOSAFETY COMMITTEE
DATE: March 13, 2026

Attendance: 9

Voting Members Present: 9

Called to Order: 10:01a.m.

Name	Expertise	Present
Linda Cassidy, MS	Non-Voting Member	
Sue Gotta, MS	rDNA; Select Agents	X
Gerald Grunwald, PhD	rDNA; Biochemistry; Cellular & Developmental Biology	X
Douglas C. Hooper, PhD	rDNA; Immunology; Gene Transfer	X
Botond Igyarto, PhD	Microbiology	X
Loretta Kelly, Esq.	Non-affiliate Community Member	X
Kathleen “Kitty” Kono	Non-Affiliate Community Member	X
Phil LaTourette, DVM	Laboratory Animal Sciences	X
Sara Meyer, PhD	Cancer Biology	
Fabienne Paumet, PhD	Cellular Biology & Biochemistry	
Drake Stierman	Voting Member	X
Megan Watson	Voting Member	X

MINUTES REVIEWED:

Minutes of the February 13, 2025, meeting were presented for review.

Motion to Provisionally Approve: Gerald Grunwald

Seconded: D.C. Hooper

Total = 9; For-9, Opposed-0, Abstained-0

The committee discussed provisional approval of the minutes after the PI names are changed from full names to initials as previously agreed upon. After the publishing of February’s meeting minutes, a note will be sent out to faculty that meeting notes are being published

NEW PROTOCOLS:

1. Principal Investigator P.A.

IBC Control #26-02-1017

Summary:

- Using LPNs (lipid nanoparticles) injected into the heart muscles of a rat, the retention of the lipid nanoparticles through the translation of mRNA will be studied to track the fate of LPNs after damage to the heart muscle.
- This is an in vivo study.
- The principal risks identified were:
 - mRNA lipid nanoparticles
- Containment has been set to ABSL-1.

Committee Review:

- This protocol did not involve either recombinant or synthetic DNA.
- The risks were adequately identified by the Principal Investigator and appropriate mitigation was described in the protocol.

- Clarifications were requested in both the protocol summary and lay description.
- A motion was made and seconded to provisionally approve this protocol. The motion was unanimously approved.

ADMINISTRATIVELY APPROVED ITEMS:

The KSI database indicates the following items have been given administrative approval since our last meeting:

March 13, 2026

Protocol ID	PI	Form Type	Comments
24-09-886	M.O.	Amendment	Updated IB, clinical trial
21-06-388	T.S.	Continuing Review	Updated personnel, added staph aureus, BL21, & ibrutinib
22-07-525-1	K.B.	Amendment	Updated protocol summary adding fluorescent labels on cells
23-11-755	P.W.	Continuing Review	Active - updated personnel only
23-06-661	P.W.	Continuing Review	Active - updated personnel only
23-06-693	A.L.	Continuing Review	Active - updated personnel only
22-03-486-1	A.M.	Continuing Review	Active - updated personnel & research location. 3 yr renewal.
24-08-881	S.W.	New	For the use of TNBS
24-10-898	P.S.	Amendment	Clinical trial - updated protocol & dose administration
22-11-604	C.C.	Amendment	Added cholera toxin
24-01-781	A.A.	Amendment	Added Mirdametnib and Dabrafenib (GSK2118436)
24-07-871	M.D.	Amendment	Updated IB, clinical trial
21-09-435	G.H.	Amendment	Added several cell lines, viruses, rDNA, & toxins
23-12-775	S.W.	Amendment	Updated personnel only
23-11-764	R.H.	Continuing Review	Active - updated research location only
24-04-836	A.P.	New	Input of previously approved paper copy into database

OTHER BUSINESS:

Sue Gotta informed the committee that ABL3 work has been suspended at the time of the meeting due to air handler issues. Replacement parts have been brought in and are hopefully being put in soon. 352 ABL3 is having issues with air balancing/air ducts, and Sue is trying to get a timeline.

Phil LaTourette Informed the committee that he has had the animals removed from JAH 6 East due to the air handler issues. Phil, along with Megan Watson, also informed the committee about the new CURIS decontamination system that was recently purchased, mainly for the use of turning over animal rooms.

Meeting Adjourned: 10:27 a.m.

Respectfully submitted for the IBC,

/s/Gerald Grunwald, PhD
 Chair, Institutional Biosafety Committee

GG/DS